BioSpace News Archive

Sol-Gel Technologies, Ltd. announced that Chief Executive Officer, Alon Seri-Levy, will present a corporate update at the 2022 Jefferies Global Healthcare Conference to be held June 8 -10, 2022 in-person, in New York, NY.

Lexicon Pharmaceuticals, Inc. announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:00 a.m. ET.

CinCor Pharma, Inc. announced that the first patient has been dosed in the Phase 2 figHTN-CKD trial evaluating baxdrostat, a highly selective aldosterone synthase inhibitor, in patients with uncontrolled hypertension and chronic kidney disease.

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced a global call for entries for their inaugural Early Career Research Award.

Cornerstone Pharmaceuticals, Inc., a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, announced that the Company and its partners will present three abstracts at the American Society of Clinical Oncology Annual Meeting taking place June 3 – June 7, 2022 in Chicago.

Cocrystal Pharma, Inc. announces a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases for exploratory preclinical studies to evaluate the potential of Cocrystal’s 3CL protease inhibitors for the treatment of COVID-19.

TFF Pharmaceuticals, Inc. announced that President and CEO Glenn Mattes will be participating in the Jefferies Healthcare Conference being held June 8 – 10, 2022 in New York City.

Viridian Therapeutics, Inc. announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in two fireside chats at the Jefferies Healthcare Conference being held in New York on June 8 -10, 2022 and the JMP Securities Life Sciences Conference in New York on June 15 - 16, 2022.

Amolyt Pharma announced positive results from the first cohort of its clinical proof of concept trial of AZP-3601, which the company is developing as a potential treatment for hypoparathyroidism.

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.